Preferred Label : entrectinib;
MeSH synonym : N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;
UNII : L5ORF0AN1I;
Origin ID : C000607349;
UMLS CUI : C4086264;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3282234/fr/rozlytrek-entrectinib-cpnpc
2021
false
false
false
France
Product containing precisely entrectinib 200 milligram/1 each conventional release
oral capsule (clinical drug)
Product containing precisely entrectinib 100 milligram/1 each conventional release
oral capsule (clinical drug)
evaluation of the transparency committee
entrectinib
treatment outcome
insurance, health, reimbursement
entrectinib
Rozlytrek
protein kinase inhibitors
administration, oral
adult
carcinoma, non-small-cell lung
ROS1 Positive
entrectinib
benzamides
indazoles
benzamides
indazoles
---
https://www.has-sante.fr/jcms/p_3282231/fr/rozlytrek-entrectinib-tumeurs-solides
2021
false
false
false
France
French
Product containing precisely entrectinib 200 milligram/1 each conventional release
oral capsule (clinical drug)
Product containing precisely entrectinib 100 milligram/1 each conventional release
oral capsule (clinical drug)
evaluation of the transparency committee
entrectinib
protein kinase inhibitors
neoplasms
treatment outcome
insurance, health, reimbursement
entrectinib
Malignant Solid Neoplasm
Rozlytrek
administration, oral
adult
adolescent
aged
Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion (disorder)
entrectinib
benzamides
indazoles
benzamides
indazoles
---
https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
entrectinib
entrectinib
entrectinib
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
gene fusion
Solid Neoplasm
adult
adolescent
aged
neoplasm metastasis
PROS1 protein, human
administration, oral
product surveillance, postmarketing
drug interactions
contraception
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely entrectinib 200 milligram/1 each conventional release
oral capsule (clinical drug)
Product containing precisely entrectinib 100 milligram/1 each conventional release
oral capsule (clinical drug)
benzamides
indazoles
benzamides
indazoles
blood proteins
---